These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37353308)

  • 1. Dental adverse effects of sublingual buprenorphine and naloxone.
    Drug Ther Bull; 2023 Aug; 61(8):115. PubMed ID: 37353308
    [No Abstract]   [Full Text] [Related]  

  • 2. Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease.
    Etminan M; Rezaeianzadeh R; Kezouh A; Aminzadeh K
    JAMA; 2022 Dec; 328(22):2269-2271. PubMed ID: 36511932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual buprenorphine-naloxone precipitated withdrawal-A case report with review of literature and clinical considerations.
    Bhatia G; Sarkar S
    Asian J Psychiatr; 2020 Oct; 53():102121. PubMed ID: 32460142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of the newer class of opioid antagonists in pregnancy.
    Poon S; Pupco A; Koren G; Bozzo P
    Can Fam Physician; 2014 Jul; 60(7):631-2, e348-9. PubMed ID: 25022635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine/naloxone and dental caries: a case report.
    Suzuki J; Park EM
    Am J Addict; 2012; 21(5):494-5. PubMed ID: 22882403
    [No Abstract]   [Full Text] [Related]  

  • 8. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Naloxone Component of Buprenorphine/Naloxone: Discouraging Misuse, but at What Cost?
    Gregg J; Hartley J; Lawrence D; Risser A; Blazes C
    J Addict Med; 2023 Jan-Feb 01; 17(1):7-9. PubMed ID: 35913990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine alone or with naloxone: Which is safer?
    Kelty E; Cumming C; Troeung L; Hulse G
    J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual Buprenorphine-Naloxone Exposure and Dental Disease-Reply.
    Etminan M; Rezaeianzadeh R
    JAMA; 2023 Apr; 329(14):1224-1225. PubMed ID: 37039794
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual Buprenorphine-Naloxone Exposure and Dental Disease.
    Brothers TD; Lewer D; Bonn M
    JAMA; 2023 Apr; 329(14):1224. PubMed ID: 37039797
    [No Abstract]   [Full Text] [Related]  

  • 14. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.
    Rosenthal RN; Ling W; Casadonte P; Vocci F; Bailey GL; Kampman K; Patkar A; Chavoustie S; Blasey C; Sigmon S; Beebe KL
    Addiction; 2013 Dec; 108(12):2141-9. PubMed ID: 23919595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting.
    Leshner AI
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S103-4. PubMed ID: 12738354
    [No Abstract]   [Full Text] [Related]  

  • 16. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
    Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
    J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
    Gunderson EW; Hjelmström P; Sumner M;
    Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ischemic Hand Complications From Intra-Arterial Injection of Sublingual Buprenorphine/Naloxone Among Patients With Opioid Dependency.
    Wilson RM; Elmaraghi S; Rinker BD
    Hand (N Y); 2017 Sep; 12(5):507-511. PubMed ID: 28832211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients.
    Baykara S; Alban K
    Psychiatry Res; 2019 Feb; 272():450-453. PubMed ID: 30611963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.